Known as Vizz, the once-daily eye drops treat age-related blurry near vision — also known as presbyopia — for up to 10 hours at a time.

Vizz is the first and only aceclidine-based eye drop to improve near vision in adults with presbyopia. Vizz contracts the iris sphincter muscle resulting in a pinhole effect, achieving a pupil <2 mm, ...

VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once ...

The Companies plan to file an application with the FDA in the second half of 2025. Topline data were announced from a phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) for the ...

To schedule an appointment, call 214-220-3937 or visit keywhitman.com.

LENZ Therapeutics, Inc. ( NASDAQ: LENZ) Therapeutics, Inc. Citi's Biopharma Back to School Conference September 3, 2025 9:45 AM EDT ...

Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing will ...

With the U.S. FDA’s approval of Lenz Therapeutics Inc.’s Vizz (aceclidine ophthalmic solution), there is a third eye drop on the market for treating presbyopia. Vizz, however, is the first ...

Ophthalmologist Dr. Rupa Wong talks with host Rob Schmitz about a new eyedrop that treats presbyopia, the scientific name for age-related farsightedness. This article was originally published on ...

Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.